Repatha and Progesterone HRT Interaction: What Patients and Clinicians Need to Know

What Is the Interaction Between Repatha and Progesterone HRT?

Evolocumab and progesterone HRT do not share a classical pharmacokinetic drug-drug interaction pathway. Evolocumab is a fully human IgG2 monoclonal antibody that is broken down by non-specific proteolytic catabolism across body tissues, the same way the body clears any large protein. It does not enter the CYP450 system, is not transported by P-glycoprotein or OATP1B1/1B3, and is not renally filtered in a way that hormones could disrupt.

Because progesterone is primarily metabolized by CYP3A4 and, to a lesser extent, CYP2C19, it occupies an entirely different metabolic lane from evolocumab. The two drugs simply do not compete for the same enzymes, transporters, or receptors at a pharmacokinetic level.

"no PK interaction" is not the same as "no clinical considerations." Shared pharmacodynamic effects, particularly CNS sedation with oral micronized progesterone and the broader cardiovascular context of managing ASCVD in a patient also receiving hormone therapy, require individualized attention.

How Evolocumab Is Cleared

Evolocumab works by binding PCSK9 in the bloodstream, which prevents PCSK9 from degrading LDL receptors on hepatocytes. Once bound, the evolocumab-PCSK9 complex is internalized by the liver and degraded intracellularly. Unbound evolocumab circulates with a half-life of approximately 11-17 days following subcutaneous injection [1].

No hepatic CYP enzyme has been identified as involved in evolocumab clearance. The FDA prescribing information for evolocumab specifically states that formal drug-drug interaction studies with CYP probes were not conducted because the molecule's elimination pathway makes them unnecessary [1].

How Progesterone Is Cleared

Oral micronized progesterone (brand name Prometrium in the United States) undergoes extensive first-pass hepatic metabolism, primarily via CYP3A4, generating active metabolites including allopregnanolone, which accounts for the sedative properties seen with oral dosing. Vaginal and transdermal progesterone formulations bypass first-pass metabolism, producing much lower peak plasma levels of these sedating metabolites [2].

Neither CYP3A4 nor any other progesterone-related metabolic enzyme acts on evolocumab. The metabolic pathways run in parallel without overlap.

Pharmacodynamic Considerations: Where Caution Is Still Warranted

Even when two drugs do not interact pharmacokinetically, their combined pharmacodynamic effects can create clinically relevant situations. Three areas merit attention when a patient takes evolocumab and progesterone HRT concurrently.

Sedation from Oral Micronized Progesterone

Oral micronized progesterone generates allopregnanolone, a positive allosteric modulator of the GABA-A receptor. This mechanism produces measurable sedation, particularly in the first 1-2 hours after a bedtime dose. Most clinical guidelines recommend taking oral micronized progesterone at bedtime precisely to manage this effect [3].

Evolocumab itself does not cause sedation. However, if a patient is also taking other CNS-depressant agents (benzodiazepines, antihistamines, opioids) alongside both evolocumab and oral progesterone, the sedation burden from progesterone is additive with those other agents. Evolocumab is not part of that additive burden, but documenting the full medication list matters when counseling patients.

Vaginal progesterone (Crinone 8% gel, Endometrin) and transdermal formulations produce far lower systemic allopregnanolone levels and carry a negligible sedation risk.

Cardiovascular Risk Profile in the ASCVD Patient on HRT

This is the more clinically substantive intersection. A patient prescribed evolocumab almost certainly has established ASCVD or heterozygous/homozygous familial hypercholesterolemia. The FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C by a mean of 59% from baseline and cut the composite MACE endpoint by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001) at a median follow-up of 2.2 years [4].

Adding HRT to this clinical picture introduces a separate cardiovascular variable. The Women's Health Initiative (WHI) Memory Study and later sub-analyses established that the cardiovascular impact of HRT depends heavily on the specific formulation, route of administration, patient age, and time since menopause. The 2023 Menopause Society Position Statement clarifies that for healthy women under 60 or within 10 years of menopause onset, transdermal estrogen with micronized progesterone carries a favorable safety profile compared with older conjugated estrogen/medroxyprogesterone acetate regimens [5].

Oral synthetic progestins (notably medroxyprogesterone acetate) have shown less favorable lipid and platelet effects compared with micronized progesterone. A 2019 analysis in the journal Climacteric found that micronized progesterone was associated with a lower thrombotic risk profile than medroxyprogesterone acetate, though neither the FOURIER nor the ODISSEY OUTCOMES trial populations were stratified by progestogen type [6].

For the individual patient taking evolocumab, the treating clinician should document HRT formulation choice, assess VTE risk (using a validated tool such as the ACCP model), and recalibrate the global ASCVD risk picture at each visit.

Effect of Estrogen-Progestogen Combinations on LDL-C

Estrogen alone tends to lower LDL-C. Progestogens have a variable effect depending on androgenicity. Micronized progesterone has minimal androgenic activity and does not meaningfully offset estrogen's LDL-lowering effect [7]. Synthetic progestins with higher androgenicity (levonorgestrel, norgestrel) may partially blunt the LDL reduction from estrogen.

This matters in patients on evolocumab because the physician is monitoring LDL-C as a therapeutic endpoint. If a patient initiates or changes HRT and an unexpected change in LDL-C appears at the next lipid panel, the clinician should consider the progestogen's androgenic profile as a contributing factor before adjusting the evolocumab dose.

Repeating a fasting lipid panel 4-12 weeks after any HRT initiation or formulation change is a practical, low-cost safeguard.

Severity Classification and DDI Database Assessment

The table below presents a structured assessment of the evolocumab-progesterone HRT interaction across the four domains used by major DDI databases (Lexicomp, Micromedex, Clinical Pharmacology):

| Domain | Evolocumab + Progesterone HRT | Clinical Weight | |---|---|---| | Pharmacokinetic (CYP/PgP/UGT) | No shared pathway | Negligible | | Pharmacokinetic (protein binding) | Both protein-bound, but monoclonal antibodies bind to PCSK9, not albumin sites shared with steroids | Negligible | | Pharmacodynamic (CNS) | Oral progesterone: sedation; evolocumab: none | Low (only relevant with co-administered CNS depressants) | | Pharmacodynamic (cardiovascular) | Context-dependent; ASCVD risk staging required | Moderate (individualized) |

No major DDI database (Lexicomp, Micromedex, or Clinical Pharmacology as of January 2025) lists evolocumab and progesterone as a flagged pair. The FDA prescribing information for evolocumab (Repatha) does not list any hormonal contraceptives or HRT formulations as contraindicated or requiring precaution labeling [1].

What the Guidelines Say

ACC/AHA 2022 Cholesterol Guideline

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol does not identify hormone therapy as a contraindication to PCSK9 inhibitor use. The guideline states that for patients with ASCVD requiring additional LDL-C lowering beyond maximally tolerated statin therapy, adding a PCSK9 inhibitor is appropriate when LDL-C remains at or above 70 mg/dL [8].

Menopause Society 2023 Position Statement

The 2023 Menopause Society Position Statement on hormone therapy specifically names micronized progesterone as the preferred progestogen for women who require endometrial protection. The statement notes that the cardiovascular risk associated with body-identical progesterone is lower than with synthetic progestins, making it the preferred choice in women with pre-existing cardiovascular risk factors [5].

The direct implication for evolocumab patients: if a woman on PCSK9 inhibitor therapy needs progestogen, the available evidence favors micronized progesterone over medroxyprogesterone acetate from a cardiovascular risk standpoint.

FOURIER Trial Context

In the FOURIER trial, the enrolled population was not stratified by HRT use, as most participants were post-menopausal women and men with established cardiovascular disease [4]. HRT prevalence among female participants was not separately reported. This is a gap in the literature; no large trial has prospectively examined PCSK9 inhibitor outcomes stratified by concurrent HRT use.

That evidence gap does not signal danger. It signals that clinical decisions must rely on mechanism-based reasoning and individualized risk assessment rather than dedicated trial data.

Monitoring Parameters

Lipid Panel Schedule

Patients initiating or changing HRT while on evolocumab should have a fasting lipid panel within 4-12 weeks of the change. This is consistent with standard practice for any intervention that may shift the lipid profile. Evolocumab's LDL-C lowering is typically maximal within 4 weeks of the first dose [1], so a baseline on stable evolocumab therapy, followed by a repeat panel after HRT changes, gives a clean comparison.

VTE Assessment

Women with established ASCVD on evolocumab may carry additional VTE risk factors including older age, reduced mobility, and prior vascular events. Adding any progestogen (oral, vaginal, or transdermal) does not eliminate VTE risk, though transdermal routes are generally associated with a lower VTE signal compared to oral estrogen-progestogen combinations [5].

Clinicians should document VTE risk at baseline using a validated clinical model and revisit it if the HRT formulation changes or if new thrombotic risk factors emerge.

CNS and Fall Risk

For older patients, particularly those over 65, the sedating effect of oral micronized progesterone at night is relevant to fall risk. This has no direct pharmacological relationship to evolocumab, but both agents are likely to be co-prescribed in older women. Documenting fall history, reviewing other sedating medications, and recommending bedtime dosing of progesterone are straightforward steps.

Injection Site and Autoimmune Surveillance

Evolocumab is administered subcutaneously. Patients on HRT do not require any changes to injection site selection or frequency. No evidence suggests that estrogen or progesterone alters evolocumab's immunogenicity or its rate of anti-drug antibody formation, which was already very low (below 0.3%) in the FOURIER trial [4].

Patient Counseling Points

Patients who ask whether they can take Repatha with progesterone HRT deserve a direct, accurate answer rather than vague reassurance. These are the specific points to cover:

On interaction risk: The two medications are cleared by completely different mechanisms. Repatha does not go through the same liver enzymes as progesterone, so one does not raise or lower the other's blood level. There is no known pharmacokinetic interaction.

On sleepiness: If the patient takes oral progesterone (Prometrium), it may cause drowsiness. Repatha does not add to this. Taking progesterone at bedtime substantially reduces daytime sedation. Vaginal progesterone formulations produce much less sedation.

On cholesterol monitoring: Starting or switching HRT may shift LDL-C slightly, depending on the type of progestogen. A cholesterol check 6-8 weeks after any HRT change confirms that the Repatha dose is still hitting the LDL target.

On injections: Nothing about taking progesterone HRT changes how or where the Repatha injection is given. The schedule (every two weeks for 140 mg, or monthly for 420 mg) stays the same.

On any new symptoms: New leg swelling, chest pain, or shortness of breath while on both medications warrants prompt evaluation. These are not expected drug interaction symptoms, but they are symptoms that matter independently in a high-cardiovascular-risk patient.

Special Populations

Women with Familial Hypercholesterolemia

Women with heterozygous familial hypercholesterolemia (HeFH) represent a specific overlap group. HeFH occurs in approximately 1 in 250 individuals globally [9]. Many HeFH patients are premenopausal when diagnosed and continue LDL-lowering therapy through the menopausal transition. For these women, the question of concurrent PCSK9 inhibitor and HRT use is not rare.

The Familial Hypercholesterolaemia Studies Collaboration (FHSC) has published global registry data confirming that women with HeFH have a two-fold higher ASCVD risk than women without the condition at the same age [9]. No sub-analysis of HeFH registries has specifically examined HRT co-administration with evolocumab, but the mechanism-based evidence strongly suggests no pharmacokinetic concern. The cardiovascular risk-benefit equation for HRT in HeFH patients should be assessed by the treating lipidologist and menopause specialist together.

Transgender Women on Progestogen Therapy

Transgender women may be prescribed estrogen plus progestogen as part of gender-affirming hormone therapy. If a transgender woman also has ASCVD or FH and is on evolocumab, the same interaction framework applies: no PK interaction, and a cardiovascular risk assessment individualized to the patient's history. The 2024 Endocrine Society guideline on gender-affirming care does not contraindicate PCSK9 inhibitors in this population [10].

Older Postmenopausal Women

Women over 65 starting evolocumab are the largest demographic overlap group. HRT initiated more than 10 years after menopause carries a less favorable cardiovascular risk profile per the Menopause Society's 2023 guidance [5]. This is a clinical decision point independent of evolocumab's pharmacology, but it affects the overall risk-benefit calculation that the prescribing team must document.

Evolocumab Efficacy: Key Numbers for Clinical Context

The FOURIER trial enrolled 27,564 patients with established ASCVD on optimized statin therapy. Evolocumab reduced LDL-C from a mean baseline of 92 mg/dL to 30 mg/dL at 48 weeks. The primary MACE endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% of placebo (HR 0.85, P<0.001) [4].

The ODISSEY OUTCOMES trial (N=18,924) with alirocumab, a closely related PCSK9 inhibitor, showed a 15% relative risk reduction in MACE in post-ACS patients, with greater absolute benefit in patients with higher baseline LDL-C [11]. While alirocumab data is not directly substitutable for evolocumab, both trials establish the class effect and support the value of maintaining LDL-C lowering even as HRT variables shift the clinical picture.

In the GLAGOV trial (N=968), evolocumab 420 mg monthly on top of statin therapy produced coronary atheroma regression (mean percent atheroma volume change of -0.95% vs. +0.05% for placebo, P<0.001) at 76 weeks [12]. Regression of established plaque is a finding that strengthens the case for continuing evolocumab uninterrupted regardless of changes in concomitant HRT.

Summary of Clinical Decision Points

Prescribers managing a patient on both evolocumab and progesterone HRT should work through these specific checkpoints at each visit:

1. Confirm the progesterone formulation (oral micronized vs. Vaginal vs. Transdermal) and document whether androgenic synthetic progestins are in use.
2. Check whether the current LDL-C is at or below the patient's ASCVD-guided target (generally <70 mg/dL for high-risk patients per the 2022 ACC/AHA guideline [8]).
3. Schedule a lipid panel 4-12 weeks after any HRT initiation or formulation change.
4. Document VTE risk factors and reassess if HRT route or formulation changes.
5. Review the full medication list for other CNS depressants if the patient is using oral micronized progesterone.
6. Note that evolocumab dose and injection schedule require no adjustment for concurrent progesterone HRT.

The absence of a pharmacokinetic interaction does not reduce the importance of thorough clinical follow-up in a high-risk population. A repeat fasting lipid panel at 4-12 weeks after any change in HRT formulation remains the single most actionable monitoring step for this combination.